KRAS mutations were observed in 43% of ovarian carcinomas and in 30% of colorectal carcinomas, which do not contribute to differential diagnosis in mucinous neoplasms of the colon and ovary [5]. This evidence concerns the gene KRAS and colorectal carcinoma.